Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curazink in Mild Cognitive Impairment or Mild Alzheimer’s Disease
DRKS00015782Phase 2Completed
- Sponsor
- Medical Faculty Magdeburg
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cognitive disorder (CD) and Alzheimer's disease (AD) comparing Curazink with Placebo (2 arms). Primary endpoint: Change in inflammatory biomarkers (CRP, IL-6, iron, TGF-β1, IL-10). Started Oct 2018; status: completed.
02
Drugs
zinc histidine
03
Conditions
cognitive disorder (CD)Alzheimer's disease (AD)
Beyond the preview
Go deeper on DRKS00015782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00015782.